

Bachem – Reinforced Collaboration with DOTTIKON ES on Novel Amino Acids

Bubendorf/Basel, Switzerland, October 4, 2016 – Bachem Group (SIX: BANB) and DOTTIKON ES announce that they are extending their collaboration in the area of novel amino acids. The collaboration between the two Swiss companies covers the development, manufacturing, and distribution of innovative, enantiomerically pure amino acids, for example for peptide synthesis. Dr. José de Chastonay, Chief Marketing Officer of Bachem Holding AG, has the following to say about the partnership: “We are pleased to collaborate with DOTTIKON ES to bring innovative, new amino acid derivatives for peptide synthesis to our worldwide customer base. Due to the special chemical skills of DOTTIKON ES, special, enantiomerically pure amino acid derivatives of high quality can be manufactured very efficiently.” Bachem is the global leader in exclusive custom synthesis of peptides for preclinical and clinical pharmaceutical research. DOTTIKON ES, the specialist for hazardous reactions, provides innovative technology for the stereoselective synthesis of chiral building blocks as well as longstanding experience in chemical process development, scale-up and production.

About Bachem

Bachem is a listed technology-based company focused on peptide chemistry. The company provides a full range of services to the pharma and biotech industries. It specializes in the development of innovative, efficient manufacturing processes and the reliable production of peptide-based active pharmaceutical ingredients. A comprehensive catalog of biochemicals and exclusive custom syntheses for research labs complete the service portfolio. Headquartered in Switzerland with subsidiaries in Europe and the US, the group has a global reach with more experience and knowhow than any other company in the industry. Towards its customers, Bachem shows total commitment to quality, innovation and partnership.

Bachem. Pioneering Partner for Peptides

About DOTTIKON ES

DOTTIKON ES manufactures high-quality performance chemicals, intermediates and exclusive active pharmaceutical ingredients (APIs) for the world's leading chemical and pharmaceutical industry. The company with its production site in Dottikon (Aargau, Switzerland) is specialized in hazardous reactions and is positioning itself as strategic development and manufacturing partner. Its safety culture created over the last 100 years guides innovative use of hazardous reactions, low-temperature and high-pressure chemistry, as well as continuous processing. This shortens conventional chemical synthesis routes, increases yields, selectivities and purities, and reduces waste. The versatile technology and equipment portfolio is used to design, develop and optimize chemical processes, and scale up from kilograms to multi-tons.

DOTTIKON ES' one-site strategy allows reduced decision and communication pathways. This ensures rapid and efficient project development as well as clear and transparent communication with customers.

For more information:

Bachem Holding AG
Stephan Schindler, CFO
Tel. +41 58 595 2021
Fax: +41 58 595 2043

www.bachem.com
ir@bachem.com